ARTICLE | Emerging Company Profile
VelaVigo: Li, Zhang chart course to build global biologics player
WuXi vets’ Shanghai newco focusing on antibody innovation
January 8, 2022 2:03 AM UTC
Former WuXi colleagues Jing Li and Tong Zhang have reunited at VelaVigo to rapidly create a broad pipeline of biologics, beginning with multispecifics and ADCs, by combining Li’s discovery expertise with the dealmaking chops Zhang honed at MNCs, VCs and biotechs.
Founded in October 2021, VelaVigo (Shanghai) Ltd. — the name is a play on the Latin terms for sailing and navigation — plans to discover, develop and commercialize antibody-based therapies including bi- and trispecific antibodies and antibody-drug conjugates with a focus on innovative targets for cancer and inflammation. The company aims to develop a pipeline of two to three dozen assets within the next three years...